Medtronic has received U.S. FDA approval for BrainSense Adaptive Deep Brain Stimulation (aDBS), marking the first closed-loop DBS system for Parkinson’s disease. This system dynamically adjusts therapy based on individual brain activity in real time, improving symptom control without manual adjustments. The approval also includes the BrainSense Electrode Identifier, which speeds up DBS programming by 85%.

Developed over a decade, this technology represents the largest commercial launch of brain-computer interface (BCI) technology. The approval follows clinical trials, including the ADAPT-PD study, which demonstrated the benefits of aDBS for managing Parkinson’s symptoms.

BrainSense aDBS and EI are also available in Europe, with U.S. patient programming beginning in select healthcare systems in the coming weeks.

Source: Medtronic, "Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's," February 24, 2025.